Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network

References

Babaian, R.J., Fritsche, H., Ayala, A., Bhadkamkar, V., Johnston, D.A., Naccarato, W., and Zhang, Z. (2000). Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/ml. Urology56, 1000–1006.10.1016/S0090-4295(00)00830-XSearch in Google Scholar

Carlson, G.D., Calvanese, C.B., and Partin, A.W. (1998). An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology52, 455–461.10.1016/S0090-4295(98)00205-2Search in Google Scholar

Catalona, W.J., Partin, A.W., Slawin, K.M., Brawer, M.K., Flanigan, R.C., Patel, A., Richie, J.P., deKernion, J.B., Walsh, P.C., Scardino, P.T., et al. (1998). Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. J. Am. Med. Assoc.279, 1542–1547.10.1001/jama.279.19.1542Search in Google Scholar

Diamandis, E.P., Yousef, G.M., Luo, I., Magklara, I., and Obiezu, C.V. (2000). The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol. Metab.11, 54–60.10.1016/S1043-2760(99)00225-8Search in Google Scholar

Diamandis, E.P., Okui, A., Mitsui, S., Luo, L.Y., Soosaipillai, A., Grass, L., Nakamura, T., Howarth, D.J., and Yamaguchi, N. (2002). Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res.62, 295–300.Search in Google Scholar

Djavan, B., Remzi, M., Zlotta, A., Seitz, C., Snow, P., and Marberger, M. (2002). Novel artificial neural network for early detection of prostate cancer. J. Clin. Oncol.20, 921–929.10.1200/JCO.2002.20.4.921Search in Google Scholar

Dreiseitl, S. and Ohno-Machado, L. (2002). Logistic regression and artificial neural network classification models: a methodology review. J. Biomed. Inform.35, 352–359.10.1016/S1532-0464(03)00034-0Search in Google Scholar

Finne, P., Finne, R., Auvinen, A., Juusela, H., Aro, J., Maattanen, L., Hakama, M., Rannikko, S., Tammela, T.L., and Stenman, U. (2000). Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology56, 418–422.10.1016/S0090-4295(00)00672-5Search in Google Scholar

Haese, A., Chaudhari, M., Miller, M.C., Epstein, J.I., Huland, H., Palisaar, J., Graefen, M., Hammerer, P., Poole, E.C., O'Dowd, G.J., et al. (2003). Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma: a multiinstitutional validation study. Cancer97, 969–978.10.1002/cncr.11153Search in Google Scholar PubMed

Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., Feuer, E.J., and Thun, M.J. (2005). Cancer statistics, 2005. CA Cancer J. Clin.55, 10–30.10.3322/canjclin.55.1.10Search in Google Scholar PubMed

Kairisto, V. and Poola, A. (1995). Software for illustrative presentation of basic clinical characteristics of laboratory tests – GraphROC for Windows. Scand. J. Clin. Lab. Invest.55 (Suppl. 222), 43–60.10.3109/00365519509088450Search in Google Scholar PubMed

Lilja, H., Christensson, A., Dahlen, U., Matikainen, M.T., Nilsson, O., Pettersson, K., and Lövgren, T. (1991). Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin. Chem.37, 1618–1625.10.1093/clinchem/37.9.1618Search in Google Scholar

Magklara, A., Scorilas, A., Stephan, C., Kristiansen, G.O., Hauptmann, S., Jung, K., and Diamandis, E.P. (2000). Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology56, 527–532.10.1016/S0090-4295(00)00621-XSearch in Google Scholar

Nakamura, T., Mitsui, S., Okui, A., Kominami, K., Nomoto, T., Ukimura, O., Kawauchi, A., Miki, T., and Yamaguchi, N. (2001). Alternative splicing isoforms of hippostasin (PRSS20/KLK11) in prostate cancer cell lines. Prostate49, 72–78.10.1002/pros.1119Search in Google Scholar

Nakamura, T., Scorilas, A., Stephan, C., Jung, K., Soosaipillai, A.R., and Diamandis, E.P. (2003a). The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res.63, 6543–6546.Search in Google Scholar

Nakamura, T., Stephan, C., Scorilas, A., Yousef, G.M., Jung, K., and Diamandis, E.P. (2003b). Quantitative analysis of hippo-stasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. Urology61, 1042–1046.10.1016/S0090-4295(02)02443-3Search in Google Scholar

Polascik, T.J., Oesterling, J.E., and Partin, A.W. (1999). Prostate specific antigen: a decade of discovery – what we have learned and where we are going. J. Urol.162, 293–306.10.1097/00005392-199908000-00003Search in Google Scholar

Reckwitz, T., Potter, S.R., Snow, P.B., Zhang, Z., Veltri, R.W., and Partin, A.W. (1999). Artificial neural networks in urology: update 2000. Prostate Cancer Prostatic Dis.2, 222–226.10.1038/sj.pcan.4500374Search in Google Scholar PubMed

Stavropoulou, P., Gregorakis, A.K., Plebani, M., and Scorilas, A. (2005). Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. Clin. Chim. Acta357, 190–195.10.1016/j.cccn.2005.03.026Search in Google Scholar PubMed

Stenman, U.H. (1997). Prostate-specific antigen, clinical use and staging: an overview. Br. J. Urol.79 (Suppl. 1), 53–60.10.1111/j.1464-410X.1997.tb00802.xSearch in Google Scholar

Stenman, U.H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhkanen, K., and Alfthan, O. (1991). A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res.51, 222–226.Search in Google Scholar

Stenman, U.H., Abrahamsson, P.A., Aus, G., Lilja, H., Bangma, C., Hamdy, F.C., Boccon-Gibod, L., and Ekman, P. (2005). Prognostic value of serum markers for prostate cancer. Scand. J. Urol. Nephrol. (suppl.) 216, 64–81.10.1080/03008880510030941Search in Google Scholar PubMed

Stephan, C., Jung, K., Lein, M., Sinha, P., Schnorr, D., and Loening, S.A. (2000). Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol. Biomarkers Prev.9, 1133–1147.Search in Google Scholar

Stephan, C., Cammann, H., Semjonow, A., Diamandis, E.P., Wymenga, L.F.A., Lein, M., Sinha, P., Loening, S.A., and Jung, K. (2002a). Multicenter evaluation of an artificial neural network to increase prostate cancer detection rate and reduce unnecessary biopsies. Clin. Chem.48, 1279–1287.10.1093/clinchem/48.8.1279Search in Google Scholar

Stephan, C., Jung, K., Cammann, H., Vogel, B., Brux, B., Kristiansen, G., Rudolph, B., Hauptmann, S., Lein, M., Schnorr, D., et al. (2002b). An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: results of a 5-year investigation. Int. J. Cancer99, 466–473.10.1002/ijc.10370Search in Google Scholar PubMed

Stephan, C., Jung, K., and Sinha, P. (2002c). Tumor markers for prostatic cancer – which way in this millenium? Res. Adv. Cancer2, 147–157.Search in Google Scholar

Stephan, C., Vogel, B., Cammann, H., Lein, M., Klevecka, V., Sinha, P., Kristiansen, G., Schnorr, D., Jung, K., and Loening, S.A. (2003). Nutzung von artifiziellen neuronalen Netzwerken zur Risikoabschätzung eines Prostatakarzinoms: Biopsieindikationen im PSA-Bereich 2–20 μg/l. Urologe A42, 1221–1229.10.1007/s00120-003-0322-7Search in Google Scholar PubMed

Stephan, C., Cammann, H., and Jung, K. (2005a). Viewpoint: artificial neural networks: has the time come for their use in prostate cancer patients? Nat. Clin. Pract. Urol.2, 262–263.10.1038/ncpuro0207Search in Google Scholar PubMed

Stephan, C., Jung, K., Soosaipillai, A., Yousef, G.M., Cammann, H., Meyer, H., Xu, C., and Diamandis, E.P. (2005b). Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. BJU Int.96, 521–527.10.1111/j.1464-410X.2005.05677.xSearch in Google Scholar PubMed

Veltri, R.W., Chaudhari, M., Miller, M.C., Poole, E.C., O'Dowd, G.J., and Partin, A.W. (2002). Comparison of logistic regression and neural net modeling for prediction of prostate cancer pathologic stage. Clin. Chem.48, 1828–1834.10.1093/clinchem/48.10.1828Search in Google Scholar

Virtanen, A., Gomari, M., Kranse, R., and Stenman, U.H. (1999). Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin. Chem.45, 987–994.10.1093/clinchem/45.7.987Search in Google Scholar